Mumbai-based Highness Microelectronics is currently in the final stages of its ₹21.67 crore SME IPO. Specialized in ruggedized digital imaging and display solutions for Defense, Railways, and Healthcare, the company is seeing strong momentum as it heads toward its closing bell tomorrow.
Open IPO
Jaipur’s Emiac Technologies launches its ₹31.75 crore SME IPO on March 27, 2026. With a massive 269% revenue jump last year and a high-margin AI-content model, we dive into the ₹93–₹98 price band, the anchor investor buzz, and whether this digital powerhouse is a "Subscribe" for your portfolio.
Open IPO
Navi Mumbai’s Vivid Electromech is currently in the middle of its ₹130.54 crore IPO. Specializing in high-voltage and low-voltage electrical panels, the company has seen its profits jump 400% in just two years. We look at the Day 2 subscription trends, the ₹555 price band, and why the "Data Center" boom is their biggest tailwind.
Open IPO
Hyderabad-based Sai Parenteral's enters the final stretch of its ₹409 crore IPO. With a price band of ₹372–₹392 and a focus on high-margin injectables, the company is pitching a massive growth story. However, with a ₹0 GMP and a high P/E ratio, we break down the Day 3 subscription and the "Long-Term vs. Listing Gain" debate.
Open IPO
One of India’s top 3 basmati rice exporters, Amir Chand Jagdish Kumar, enters Day 3 of its ₹440 crore IPO. With a price band of ₹201–₹212 and a ₹7 GMP, the issue is already oversubscribed. We dive into the "Aeroplane" brand's strength, the subscription numbers, and whether the 43% EBITDA growth makes this a "Subscribe."
Upcoming IPO
Jaipur’s Emiac Technologies is set to launch its ₹31.75 crore IPO on March 27, 2026. With a massive 269% revenue growth in the last year and a niche focus on AI-driven content and automation, we look at the price band, grey market sentiment, and whether this digital powerhouse is worth the premium.
Open IPO
Navi Mumbai-based Vivid Electromech opens its ₹130.54 crore IPO today with a price band of ₹528–₹555. Boasting a massive 74% CAGR and partnerships with giants like Schneider and ABB, this electrical panel manufacturer is aiming for a 3x capacity expansion. We analyze the Day 1 subscription and the company's long-term "moat."
Open IPO
Hyderabad-based Sai Parenteral's enters Day 2 of its ₹409 crore IPO with a price band of ₹372–₹392. While Day 1 saw a muted 0.05x subscription and a flat ₹0 GMP, the company’s recent Australian acquisition and strong anchor book (including Morgan Stanley) suggest a long-term story. We break down the financials and the "Noumed" factor.
Open IPO
Mumbai-based Highness Microelectronics enters Day 2 of its ₹21.67 crore IPO with a price band of ₹114–₹120. With a ₹20 GMP (16% estimated gain) and a massive shift into the high-margin Defense and Railway sectors, we break down the subscription numbers and whether this niche display manufacturer fits your portfolio.
Open IPO
The ₹440 crore IPO of Amir Chand Jagdish Kumar (Exports) is seeing robust demand, having already crossed the 1x mark on its first day. With the price band set at ₹201–₹212 and a ₹7 GMP, we look at why Non-Institutional Investors (NIIs) are rushing in and whether the "Three Star Export House" status makes this a long-term winner.
Open IPO
Get the final day update on Tipco Engineering India Limited’s SME IPO. Check the latest Grey Market Premium (GMP), real-time subscription status, allotment dates, and whether you should subscribe on the closing day.
Open IPO
Navi Mumbai-based Vivid Electromech launches its ₹130.54 crore SME IPO on March 25, 2026. With 30+ years of experience and a massive 74% revenue growth last year, the company is targeting the rapidly expanding data center and metro rail sectors. We dive into the ₹528–₹555 price band, the flat GMP, and the ambitious 3x capacity expansion plan.
Open IPO
Hyderabad-based Sai Parenteral's Limited launched its ₹409 crore IPO today, March 24, 2026, with a price band of ₹372–₹392. With a bold move to acquire Australia’s Noumed Pharmaceuticals, the company is shifting from a domestic manufacturer to a global CDMO powerhouse. We analyze the 72x P/E valuation, the flat GMP, and the long-term potential of this injectable specialist.